Who Buys Ledipasvir from India — 90 Importers Behind a $1.1M Market

The importation of Ledipasvir from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like QUESTA CARE LIMITED (Kenya) and M/S IMOCO EXPRESS SERVICE (Turkey) function as intermediaries, procuring Ledipasvir in bulk to supply to local pharmacies and healthcare providers. Their purchasing patterns typically involve large, periodic orders to maintain a steady supply chain.

• Hospital Groups: Organizations such as FIRST PHARMACY (U) LTD (Uganda) and G.O. CARE MULTI ACTIVITIES COMPANY (Sudan) represent hospital networks that import Ledipasvir directly to ensure consistent availability for patient treatment. Their procurement is often characterized by regular, sizable orders aligned with patient demand and treatment protocols.

• Retail Chains: Entities like SKIN LINE LOGISTIC (Iraq) and STR INTERNATIONAL TRADING CO LTD (Cambodia) are retail pharmacy chains that import Ledipasvir to stock their outlets. Their purchasing behavior includes frequent, moderate-sized orders to meet consumer demand while managing inventory levels effectively.

• Re-exporters: Companies such as EMIRATES POST COMPANY (United Arab Emirates) may act as re-exporters, importing Ledipasvir with the intent to distribute it to neighboring regions. Their order patterns can be irregular, influenced by market demand fluctuations in target export destinations.

• Contract Manufacturers: While not explicitly identified among the top buyers, contract manufacturers could import Ledipasvir for formulation into finished pharmaceutical products. Their procurement would typically involve large, consistent orders to support continuous production cycles.

The repeat buyer rate of 40.0% indicates a substantial proportion of buyers engage in ongoing procurement, reflecting sustained demand and the establishment of long-term supply relationships.

The top five importing countries have distinct regulatory frameworks for the importation of pharmaceuticals like Ledipasvir:

• Kyrgyzstan:
• Regulatory Authority: Department of Drug Provision and Medical Equipment under the Ministry of Health.
• Import Registration Process: Requires submission of a registration dossier, including quality, safety, and efficacy data.
• Estimated Timeline: Approximately 6-12 months.
• Import Tariff/Duty: Typically ranges from 0% to 5% for pharmaceuticals under HS Code 30049099.

• Uzbekistan:
• Regulatory Authority: Agency for the Development of the Pharmaceutical Industry under the Ministry of Health.
• Import Registration Process: Involves dossier submission, local clinical trials, and facility inspections.
• Estimated Timeline: Approximately 12-18 months.
• Import Tariff/Duty: Generally 0% for essential medicines under HS Code 30049099.

• Kenya:
• Regulatory Authority: Pharmacy and Poisons Board (PPB).
• Import Registration Process: Submission of a comprehensive dossier, GMP certification, and possible local clinical evaluations.
• Estimated Timeline: Approximately 6-12 months.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 are typically exempt from import duties.

• Kazakhstan:
• Regulatory Authority: Committee for Control of Medical and Pharmaceutical Activities under the Ministry of Health.
• Import Registration Process: Requires submission of registration dossier, GMP compliance, and potential local clinical trials.
• Estimated Timeline: Approximately 12-24 months.
• Import Tariff/Duty: Generally 0% for pharmaceuticals under HS Code 30049099.

• Azerbaijan:
• Regulatory Authority: Pharmaceutical and Medical Devices Agency under the Ministry of Health.
• Import Registration Process: Involves dossier submission, GMP certification, and potential local clinical trials.
• Estimated Timeline: Approximately 12-18 months.
• Import Tariff/Duty: Typically 0% for essential medicines under HS Code 30049099.

These regulatory processes and tariffs are subject to change; it is advisable to consult the respective national regulatory authorities for the most current information.

The demand for Ledipasvir in importing countries is primarily driven by the prevalence of Hepatitis C, for which Ledipasvir is a key component in treatment regimens. According to the World Health Organization (WHO), as of 2025, approximately 58 million people globally were living with chronic Hepatitis C infection, with a significant burden in low- and middle-income countries. This high disease prevalence necessitates effective antiviral treatments like Ledipasvir.

Government healthcare programs and the expansion of universal health coverage have further stimulated demand. Many countries have integrated Hepatitis C treatment into their national health strategies, often supported by international organizations such as the WHO and the Global Fund. The inclusion of Ledipasvir in the WHO Essential Medicines List facilitates its procurement through tender-based purchasing mechanisms, ensuring broader access. Our data indicates that between 2022 and 2026, 90 buyers across 44 countries imported Ledipasvir from India, reflecting a widespread and sustained market opportunity for this antiviral medication.

The importation of Ledipasvir from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like QUESTA CARE LIMITED (Kenya) and M/S IMOCO EXPRESS SERVICE (Turkey) function as intermediaries, procuring Ledipasvir in bulk to supply to local pharmacies and healthcare providers. Their purchasing patterns typically involve large, periodic orders to maintain a steady supply chain.

• Hospital Groups: Organizations such as FIRST PHARMACY (U) LTD (Uganda) and G.O. CARE MULTI ACTIVITIES COMPANY (Sudan) represent hospital networks that import Ledipasvir directly to ensure consistent availability for patient treatment. Their procurement is often characterized by regular, sizable orders aligned with patient demand and treatment protocols.

• Retail Chains: Entities like SKIN LINE LOGISTIC (Iraq) and STR INTERNATIONAL TRADING CO LTD (Cambodia) are retail pharmacy chains that import Ledipasvir to stock their outlets. Their purchasing behavior includes frequent, moderate-sized orders to meet consumer demand while managing inventory levels effectively.

• Re-exporters: Companies such as EMIRATES POST COMPANY (United Arab Emirates) may act as re-exporters, importing Ledipasvir with the intent to distribute it to neighboring regions. Their order patterns can be irregular, influenced by market demand fluctuations in target export destinations.

• Contract Manufacturers: While not explicitly identified among the top buyers, contract manufacturers could import Ledipasvir for formulation into finished pharmaceutical products. Their procurement would typically involve large, consistent orders to support continuous production cycles.

The repeat buyer rate of 40.0% indicates a substantial proportion of buyers engage in ongoing procurement, reflecting sustained demand and the establishment of long-term supply relationships.

The top five importing countries have distinct regulatory frameworks for the importation of pharmaceuticals like Ledipasvir:

• Kyrgyzstan:
• Regulatory Authority: Department of Drug Provision and Medical Equipment under the Ministry of Health.
• Import Registration Process: Requires submission of a registration dossier, including quality, safety, and efficacy data.
• Estimated Timeline: Approximately 6-12 months.
• Import Tariff/Duty: Typically ranges from 0% to 5% for pharmaceuticals under HS Code 30049099.

• Uzbekistan:
• Regulatory Authority: Agency for the Development of the Pharmaceutical Industry under the Ministry of Health.
• Import Registration Process: Involves dossier submission, local clinical trials, and facility inspections.
• Estimated Timeline: Approximately 12-18 months.
• Import Tariff/Duty: Generally 0% for essential medicines under HS Code 30049099.

• Kenya:
• Regulatory Authority: Pharmacy and Poisons Board (PPB).
• Import Registration Process: Submission of a comprehensive dossier, GMP certification, and possible local clinical evaluations.
• Estimated Timeline: Approximately 6-12 months.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 are typically exempt from import duties.

• Kazakhstan:
• Regulatory Authority: Committee for Control of Medical and Pharmaceutical Activities under the Ministry of Health.
• Import Registration Process: Requires submission of registration dossier, GMP compliance, and potential local clinical trials.
• Estimated Timeline: Approximately 12-24 months.
• Import Tariff/Duty: Generally 0% for pharmaceuticals under HS Code 30049099.

• Azerbaijan:
• Regulatory Authority: Pharmaceutical and Medical Devices Agency under the Ministry of Health.
• Import Registration Process: Involves dossier submission, GMP certification, and potential local clinical trials.
• Estimated Timeline: Approximately 12-18 months.
• Import Tariff/Duty: Typically 0% for essential medicines under HS Code 30049099.

These regulatory processes and tariffs are subject to change; it is advisable to consult the respective national regulatory authorities for the most current information.

The demand for Ledipasvir in importing countries is primarily driven by the prevalence of Hepatitis C, for which Ledipasvir is a key component in treatment regimens. According to the World Health Organization (WHO), as of 2025, approximately 58 million people globally were living with chronic Hepatitis C infection, with a significant burden in low- and middle-income countries. This high disease prevalence necessitates effective antiviral treatments like Ledipasvir.

Government healthcare programs and the expansion of universal health coverage have further stimulated demand. Many countries have integrated Hepatitis C treatment into their national health strategies, often supported by international organizations such as the WHO and the Global Fund. The inclusion of Ledipasvir in the WHO Essential Medicines List facilitates its procurement through tender-based purchasing mechanisms, ensuring broader access. Our data indicates that between 2022 and 2026, 90 buyers across 44 countries imported Ledipasvir from India, reflecting a widespread and sustained market opportunity for this antiviral medication.